国家科技部中国科技论文统计源期刊   中国科技核心期刊   WHO西太平洋地区医学索引(WPRIM)收录期刊   湖北优秀期刊
《药物流行病学杂志》官方网站与投审稿系统变更通知<点击查看详情>
贞芪扶正胶囊配合化疗治疗晚期恶性肿瘤临床观察
Clinical Observation of the Treatment of Advanced Cancer with Zhenqi Fuzheng Capsules in the Combination of Chemotherapy
投稿时间:2005-09-27  修订日期:2005-10-27
DOI:
中文关键词:  贞芪扶正胶囊  行为状态评分  细胞免疫  化学治疗  肿瘤  恶性
英文关键词:Zhenqi Fuzheng capsules  KPS scale  Cytoimmunity  Chemotherapy  Cancer
基金项目:
刘素勤  孙亮新  班丽英  周涛
大连医科大学附属第一医院肿瘤科,辽宁大连116011
摘要点击次数: 2775
全文下载次数: 116
中文摘要:
      目的:观察贞芪扶正胶囊配合化疗治疗晚期恶性肿瘤的疗效、不良反应、KPS评分及细胞免疫功能变化。方法:观察组患者100例,予贞芪扶正胶囊4粒,bid,po,于化疗前3d开始至化疗2周期结束后7d为1疗程:对照组50例只给予化疗。观察疗效、毒副反应、KPS评分及细胞免疫功能变化。结果:两组化疗疗效无差异:观察组出现WBC减少少于对照组(61.0%vs78.0%),化疗后KPS评分上升,CD4/CD8比值、NK阳性细胞百分率化疗后提高,差异显著(P〈0.05)。结论:贞芪扶正胶囊配合化疗治疗晚期恶性肿瘤,WBC减少发生率低,可提高患者KPS评分及细胞免疫功能,宜作为化疗的常规辅助中药用药。
英文摘要:
      Objective: To evaluate the clinical efficacy, side effect, KPS scale and cytoimmunity function of Zhenqi Fuzheng capsules in the combination of chemotherapy in the treatment of advanced cancer. Method: 100 patients received Zhenqi Fuzheng capsules 4#, bid, po and chemotherapy for 2 courses. Fifty patients received chemotherapy as control group. Result: The overall response rates were 38.0% vs 34.0% , and the occurrence of leucopenia was 61.0% vs 78. 0% (P <0. 05 ) , the improvement of KPS scale and both CD4/CD8 and NK ratio was observed in Zhenqi Fuzheng capsules group (P <0. 05). Conclusion: Zhenqi Fuzheng capsules can decrease the occurrence of leucopenia and improve the KPS scale and cytoimmunity function in the period of chemotherapy.
查看全文  查看/发表评论  下载PDF阅读器
关闭